BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M; Zilucoplan MG Study Group. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol 2020;77:582-92. [PMID: 32065623 DOI: 10.1001/jamaneurol.2019.5125] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 40.0] [Reference Citation Analysis]
Number Citing Articles
1 Bennani HN, Lagrange E, Noble J, Malvezzi P, Motte L, Chevallier E, Rostaing L, Jouve T. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review. J Clin Apher 2021;36:348-63. [PMID: 33349954 DOI: 10.1002/jca.21868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Habib AA, Ahmadi Jazi G, Mozaffar T. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve 2020;62:579-92. [PMID: 32462710 DOI: 10.1002/mus.26919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schneider-Gold C, Gilhus NE. Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord 2021;14:17562864211065406. [PMID: 34987614 DOI: 10.1177/17562864211065406] [Reference Citation Analysis]
4 Farrugia ME, Goodfellow JA. A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature. Front Neurol 2020;11:604. [PMID: 32733360 DOI: 10.3389/fneur.2020.00604] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Takamori M. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability. Front Mol Neurosci 2020;13:86. [PMID: 32547365 DOI: 10.3389/fnmol.2020.00086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Thomsen JLS, Andersen H. Outcome Measures in Clinical Trials of Patients With Myasthenia Gravis. Front Neurol 2020;11:596382. [PMID: 33424747 DOI: 10.3389/fneur.2020.596382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Curr Opin Neurol 2020;33:545-52. [PMID: 32833750 DOI: 10.1097/WCO.0000000000000858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
8 Alabbad S, AlGaeed M, Sikorski P, Kaminski HJ. Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs 2020;34:557-66. [PMID: 32915379 DOI: 10.1007/s40259-020-00443-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A. Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 2021;42:1367-75. [PMID: 33543421 DOI: 10.1007/s10072-021-05077-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cavalcante P, Mantegazza R, Bernasconi P. Pharmacogenetic and pharmaco-miR biomarkers for tailoring and monitoring myasthenia gravis treatments. Expert Review of Precision Medicine and Drug Development 2020;5:317-29. [DOI: 10.1080/23808993.2020.1804865] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
12 Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov 2021;20:309-25. [PMID: 33536635 DOI: 10.1038/s41573-020-00135-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 42.0] [Reference Citation Analysis]
13 Mann H, Vencovský J. Clinical Trials in Myositis: Where Do We Stand? Curr Treat Options in Rheum 2021;7:222-42. [DOI: 10.1007/s40674-021-00180-3] [Reference Citation Analysis]
14 Li J, Liu B. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy. Cytokine Growth Factor Rev 2021;58:75-81. [PMID: 33558131 DOI: 10.1016/j.cytogfr.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev 2021;20:102712. [PMID: 33197578 DOI: 10.1016/j.autrev.2020.102712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Li Y, Yi JS, Howard JF Jr, Chopra M, Russo MA, Guptill JT. Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clin Immunol 2021;231:108830. [PMID: 34450290 DOI: 10.1016/j.clim.2021.108830] [Reference Citation Analysis]
17 Xiao H, Wu K, Liang X, Li R, Lai KP. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. Front Immunol 2021;12:715036. [PMID: 34456922 DOI: 10.3389/fimmu.2021.715036] [Reference Citation Analysis]
18 De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, Nardo G, Van Weehaeghe D, Niccolai E, Prtenjaca N, Sakowski SA, Bendotti C, Mazzini L. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neurosci Biobehav Rev 2021;127:958-78. [PMID: 34153344 DOI: 10.1016/j.neubiorev.2021.06.027] [Reference Citation Analysis]
19 Kamalinia G, Grindel BJ, Takahashi TT, Millward SW, Roberts RW. Directing evolution of novel ligands by mRNA display. Chem Soc Rev 2021;50:9055-103. [PMID: 34165126 DOI: 10.1039/d1cs00160d] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Mané-Damas M, Molenaar PC, Ulrichts P, Marcuse F, De Baets MH, Martinez-Martinez P, Losen M. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmun Rev 2022;:103104. [PMID: 35452851 DOI: 10.1016/j.autrev.2022.103104] [Reference Citation Analysis]
21 Ayzenberg I, Kleiter I. [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease]. Nervenarzt 2021;92:334-48. [PMID: 33783551 DOI: 10.1007/s00115-021-01090-4] [Reference Citation Analysis]
22 Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. Autoimmun Rev 2021;20:102800. [PMID: 33722749 DOI: 10.1016/j.autrev.2021.102800] [Reference Citation Analysis]
23 Muldur S, Vadysirisack DD, Ragunathan S, Tang Y, Ricardo A, Sayegh CE, Irimia D. Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices. Front Immunol 2021;12:777932. [PMID: 34899737 DOI: 10.3389/fimmu.2021.777932] [Reference Citation Analysis]
24 Ding Y, Ting JP, Liu J, Al-Azzam S, Pandya P, Afshar S. Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics. Amino Acids 2020;52:1207-26. [PMID: 32945974 DOI: 10.1007/s00726-020-02890-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
25 Chen Y, Chu JMT, Chang RCC, Wong GTC. The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration. Biomolecules 2022;12:337. [PMID: 35204837 DOI: 10.3390/biom12020337] [Reference Citation Analysis]
26 Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol 2021;43:757-71. [PMID: 34698894 DOI: 10.1007/s00281-021-00892-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. The Lancet Neurology 2022;21:189-202. [DOI: 10.1016/s1474-4422(21)00463-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Gorman DM, Lee J, Payne CD, Woodruff TM, Clark RJ. Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids 2021;53:143-7. [PMID: 33398524 DOI: 10.1007/s00726-020-02921-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
30 Vanoli F, Mantegazza R. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management. Neurotherapeutics 2022. [PMID: 35165857 DOI: 10.1007/s13311-022-01181-3] [Reference Citation Analysis]
31 Jiao L, Li H, Guo S. Eculizumab treatment for myasthenia gravis subgroups: 2021 update. J Neuroimmunol 2022;362:577767. [PMID: 34823117 DOI: 10.1016/j.jneuroim.2021.577767] [Reference Citation Analysis]
32 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Reference Citation Analysis]
33 Jia C, Tan Y, Zhao M. The complement system and autoimmune diseases. Chronic Diseases and Translational Medicine. [DOI: 10.1002/cdt3.24] [Reference Citation Analysis]
34 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol 2020;11:538. [PMID: 32714266 DOI: 10.3389/fneur.2020.00538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K. Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 2020;10:479. [PMID: 33088671 DOI: 10.1007/s13205-020-02464-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Mantegazza R, Antozzi C. From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research. Front Neurol 2020;11:981. [PMID: 32982957 DOI: 10.3389/fneur.2020.00981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 2021;12:696385. [PMID: 34795626 DOI: 10.3389/fneur.2021.696385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement Inhibition for the Treatment of Myasthenia Gravis. Immunotargets Ther 2020;9:317-31. [PMID: 33365280 DOI: 10.2147/ITT.S261414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Mantegazza R, Cavalcante P. Eculizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther 2020;20:991-8. [PMID: 32602752 DOI: 10.1080/14712598.2020.1786530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Howard JF Jr, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs 2021;30:483-93. [PMID: 33792453 DOI: 10.1080/13543784.2021.1897567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 2022. [PMID: 34989427 DOI: 10.1002/mus.27476] [Reference Citation Analysis]
43 Albazli K, Kaminski HJ, Howard JF Jr. Complement Inhibitor Therapy for Myasthenia Gravis. Front Immunol 2020;11:917. [PMID: 32582144 DOI: 10.3389/fimmu.2020.00917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
44 Cortés-Vicente E, Álvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, Casasnovas C, Gómez-Caravaca MT, Pardo J, Ramos-Fransi A, Pelayo-Negro AL, Gutiérrez-Gutiérrez G, Turon-Sans J, López de Munain A, Guerrero-Sola A, Jericó I, Martín MA, Mendoza MD, Morís G, Vélez-Gómez B, Garcia-Sobrino T, Pascual-Goñi E, Reyes-Leiva D, Illa I, Gallardo E. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 2022. [PMID: 35080153 DOI: 10.1002/acn3.51492] [Reference Citation Analysis]
45 Giorgio C, Zippoli M, Cocchiaro P, Castelli V, Varrassi G, Aramini A, Allegretti M, Brandolini L, Cesta MC. Emerging Role of C5 Complement Pathway in Peripheral Neuropathies: Current Treatments and Future Perspectives. Biomedicines 2021;9:399. [PMID: 33917266 DOI: 10.3390/biomedicines9040399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Siddiqi ZA, Khan W, Hussain FS. Rituximab in Myasthenia Gravis - Where do we stand? Expert Opin Biol Ther 2021;21:1013-23. [PMID: 33566716 DOI: 10.1080/14712598.2021.1889509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Beladakere Ramaswamy S, Singh S, Hooshmand S, Junsang C, Sweeney M, Govindarajan R. Current and Upcoming Treatment Modalities in Myasthenia Gravis. J Clin Neuromuscul Dis 2021;23:75-99. [PMID: 34808650 DOI: 10.1097/CND.0000000000000377] [Reference Citation Analysis]